State Street
INKT icon

State Street’s MiNK Therapeutics INKT Stock Holding History

State Street’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,552
Closed -$17.8K – 4301
2024
Q4 		$17.8K Hold
2,552
– – ﹤0.01% 4243
2024
Q3 		$19.1K Hold
2,552
– – ﹤0.01% 4230
2024
Q2 		$24.2K Sell
2,552
-8
-0.3% -$78 ﹤0.01% 4258
2024
Q1 		$23.3K Sell
2,560
-10
-0.4% -$93 ﹤0.01% 4280
2023
Q4 		$27.6K Hold
2,570
– – ﹤0.01% 4299
2023
Q3 		$30.1K Sell
2,570
-307
-11% -$5K ﹤0.01% 4379
2023
Q2 		$60.4K Buy
2,877
+1,766
+159% +$35.4K ﹤0.01% 4374
2023
Q1 		$21.3K Hold
1,111
– – ﹤0.01% 4679
2022
Q4 		$28.7K Hold
1,111
– – ﹤0.01% 4675
2022
Q3 		$23K Buy
+1,111
New +$21.9K ﹤0.01% 4807
2022
Q2 		– Sell
-1,678
Closed -$38K – 4958
2022
Q1 		$38K Buy
1,678
+485
+41% +$14.6K ﹤0.01% 4837
2021
Q4 		$53K Buy
+1,193
New +$142K ﹤0.01% 4692

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
C
Covestor London, United Kingdom $144M AUM 37.32% 1-Year Est. Return

State Street's INKT Position: Q1 2025 in Review

State Street sold out of MiNK Therapeutics (INKT) in Q1 2025, closing a stake of 2,552 shares — an estimated $17.8K sold.

State Street first reported a position in INKT in Q4 2021 and held it in 12 quarters. The position peaked at $60.4K in Q2 2023. 17 funds tracked by Wall St. Rank hold INKT as of Q1 2025.

  • State Street reported no remaining MiNK Therapeutics position as of Q1 2025 after selling out during the quarter.
  • State Street sold 2,552 MiNK Therapeutics shares in Q1 2025, an estimated $17.8K.
  • State Street first reported a position in MiNK Therapeutics in Q4 2021 and held it in 12 quarters.
  • State Street's MiNK Therapeutics position peaked at $60.4K in Q2 2023.
  • 17 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2025.

Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.